INTRODUCTION
STUDY GOALS AND OBJECTIVES
BCC’s goal for this study is to determine the specific applications and global market demand for DNA vaccine products over a 5-year period from 2009 to 2014. Our particular interest is to analyze and quantify the DNA vaccines market potential by disease type, end-use market, and technology. We also identify emerging growth opportunities in DNA vaccine delivery technologies, adjuvants, and synthetic genes.
Our key objective is to present a comprehensive analysis of the emerging DNA vaccine industry, with an emphasis on products and technologies that are commercially important in the 2009 to 2014 time period. The role of DNA vaccines within the overall vaccine industry is examined. We highlight high growth and market potential segments of the industry. This analysis provides a quantitative market basis for biotechnology, pharmaceutical, adjuvant, and gene delivery companies to make strategic choices about DNA vaccine technologies and markets. The report will be particularly useful to companies supplying DNA vaccine components and systems, including synthetic genes, DNA delivery technologies, and adjuvants.
In addition, the study will benefit a wide range of life-science companies that supply enabling technologies for vaccine discovery and development, such as micro fluidics, nanotechnology, and genomics and proteomics tools.
REASONS FOR DOING THE STUDY
The vaccine industry is rapidly changing from a mostly empirical approach to a rational design approach. Rapid developments in molecular biology, DNA synthesis, and immunobiology enable rational design approaches. These technologies allow highly targeted vaccines aimed at specific epitopes. The result is new vaccines for a wider range of diseases than was previously feasible, including a new class of therapeutic vaccines. These new technologies allow pharmaceutical firms to discover and develop high-value vaccines for novel applications, creating a substantial new market opportunity.
DNA vaccines have many potential advantages, including specific targeting, use of multiple genes to enhance immunity, and reduced risk compared with conventional vaccines. Translating the advantages of DNA vaccines into the clinic has historically been difficult; however, new advances in the fields of vaccine design and DNA delivery are addressing the previous issues. Achievements in these fields promise to overcome the translational hurdles and create strategic opportunity. This report analyzes these trends and their effects on the future markets for DNA vaccines.
The technological and structural changes occurring in the vaccine industry are strong driving forces for revitalizing this particular market and providing new growth opportunities. It is important that biotechnology and pharmaceutical firms understand the technology and market dynamics within this industry in order to best develop strategic plans and actions.
Based on these market and technology dynamics, it is especially timely to examine the future DNA vaccines markets.
INTENDED AUDIENCE
We have compiled a study of DNA vaccine technologies that will be commercially important in the major market segments, including cancer, infectious diseases, animal health, allergies, and biodefense.
We present DNA vaccine delivery and synthesis technologies; growth driving forces; product formats; market applications; clinical trials; industry structure and alliances; and global sales forecasts for the period 2009 through 2014. We estimate the future use of DNA vaccines in the important disease markets, and by technology.
This report will serve as a useful industry guide for biotechnology, DNA plasmid, gene therapy, DNA delivery, pharmaceutical, vaccine, animal health, and biodefense companies; as well as for suppliers of genetic tools, synthetic genes, and vaccine adjuvants. It will also be of interest to professionals within the regulatory agencies to understand the scope and pace of DNA vaccine technologies as they move from clinical trials into the market.
SCOPE OF REPORT
The study scope includes DNA vaccine products that are commercial or likely to be commercialized within the next 5 years. Both human and animal health markets are studied. DNA vaccine delivery technologies are also included. DNA vaccine candidates in clinical trials are examined by indication, and future market growth from 2009 through 2014 is estimated.
The role that DNA vaccines play in the overall vaccines industry is examined, as well as how the vaccine industry structure and dynamics are changing.
We examine DNA synthesis, biotechnology, and pharmaceuticals firms; strategic industry alliances; and the role of gene delivery and synthesis technologies. The major markets for DNA vaccines, including infectious diseases, cancers, animal health, allergies, and biodefense, are analyzed and the main companies in these fields are highlighted.
METHODOLOGY
Both primary and secondary research methodologies were used to prepare this report. BCC Research surveyed key users and producers in each of the end-user market segments and technology fields that will be commercially important during the next 5 years. Interviews with industry thought leaders were conducted, and an extensive review of secondary sources was done, as well as secondary market research was performed.
A vaccine value-chain method is used to study competitor, technology, and market positioning.
Based on our analysis, we project the future applications of DNA vaccines by market segment and technology type, and forecast sales revenues for 2009 through 2014.
INFORMATION SOURCES
BCC surveyed biotechnology, pharmaceutical, and gene synthesis companies to obtain data for this study. Included were life-science research tools, drug, biotechnology, DNA synthesis firms, as well as leading life-science research institutions. We also spoke with industry thought leaders. In addition, we compiled data from secondary sources, including industry, trade, and government.
ANALYST CREDENTIALS
The author, John Bergin, has written previous BCC biotechnology reports entitled Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics; Global Biochip Markets: Microarrays and Lab-on-a-chip; RNA Interference in the Post-Genomics Era: Markets and Technologies; DNA Sequencing: Emerging Technologies and Markets; Biologic Imaging Reagents: Future Technologies and Markets and Synthetic Biology. Mr. Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company, as well as executive management positions with an emerging nanotechnology company. Mr. Bergin holds the following degrees: B.S. Chemistry, M.S. Biotechnology, and Masters of Business Administration.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
- Examine BCC’s complete catalog of Market Research Reports and place direct orders
- Subscribe to any of BCC’s many industry newsletters
- Read announcements of recently published reports and newly launched newsletters
- Register for BCC’s well-known conferences
- Request additional information on any BCC product
- Take advantage of special offers
DISCLAIMER
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.
Report Code: BIO067A, Published: September 2009, Analyst: John Bergin
